Tvardi Therapeutics, Inc. cotiza a 1.06 USD y tiene una capitalización bursátil de $14M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The compa…
| Periodo | 2026-11 | 2026-08 | 2026-08 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.69 | — | $-0.78 |
| Estimado | $-0.57 | $-0.63 | $-0.63 | $-0.57 |
| Sorpresa | — | -9.5% | — | -36.8% |
| Métrica | TVRD | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -87.0% | -40.4% | -46.6% |
| ROA | -56.8% | -32.0% | -24.8% |
| Current Ratio | 2.86 | 2.84 | +0.02 |
| Debt / Equity | — | 0.28 | — |